CMMB · Chemomab Therapeutics Ltd. American Depositary Share
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CMMB by emailGet an email when CMMB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CMMB, unsubscribe in one click. Privacy
📣 What CMMB Says Is Next
first half of 2028 · “Upon completion of the Merger, the combined company is expected to operate as Scipher Medicine Corporation and trade on the Nasdaq Capital Market under the ticker symbol “SCIP.” The combined company plans to initially focus on advancing nebokitug, a first-in-class clinical-stage anti-CCL24 antibody, into a Phase 2 clinical trial for the treatment of rheumatoid arthritis, with topline results expected in the first half of 2028.”
Company press release, Aug 19, 2026 · SEC filing
in 2026 · “Planned Phase 2 study overview Together with Scipher, we expect to complete pre-IND activities and submit an IND in 2026; The combined company expect to obtain IND approval and begin Phase 2 recruitment in the first half of 2027; complete enrollment during the second half of 2027; and report 12-week Phase 2 data in the first half of 2028.”
Company press release, Aug 19, 2026 · SEC filing
H1 2028 · “A topline readout of the RA Phase 2 trial results is expected in H1 2028.”
Company press release, Jul 8, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CMMB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CMMB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.